The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC
Open accessAbstract
PURPOSE IMpower110 previously demonstrated significant overall survival (OS) benefit with atezolizumab versus chemotherapy in patients with treatment-naive EGFR/ALK-negative (WT) metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression (≥50% on tumor cells [TC] or ≥10% on tumor-infiltrating immune cells [IC], per SP142 immunohistochemistry assay). We present primary OS analyses in lower PD-L1 expression groups and an updated, exploratory analysis in the high PD-L1 expression group. PATIENTS AND METHODS This open-label, phase 3 trial randomized patients with PD-L1 expression on ≥1% of TC or IC to receive atezolizumab or platinum-based chemotherapy. The primary endpoint was OS, hierarchically tested in PD-L1 expression WT subgroups: first the high PD-L1 expression subgroup, then the high-or-intermediate PD-L1 expression subgroup (≥5% on TC or IC), and then the any PD-L1 expression subgroup (≥1% on TC or IC). RESULTS The any PD-L1 expression WT population included 554 patients (excluded 18 EGFR/ALK-positive patients). With 17 months' additional follow-up, OS improvement in the atezolizumab versus chemotherapy arm was not statistically significant in high-or-intermediate PD-L1 expression WT patients (n=328; HR, 0.87 [95% CI, 0.66-1.14]; P=0.3091; median, 19.9 vs 16.1 months), precluding formal OS testing in any PD-L1 expression WT patients. Exploratory analysis in high PD-L1 expression WT patients (n=205) showed maintained OS benefit in the atezolizumab arm (HR, 0.76 [95% CI, 0.54-1.09]; median, 20.2 vs 14.7 months). Updated safety data continued to favor atezolizumab. CONCLUSION Statistical significance for OS was not demonstrated in the high-or-intermediate expression WT group and, as a result, OS in the any PD-L1 expression WT group was not formally tested. No new safety signals were seen. This updated analysis of IMpower110 supports using atezolizumab in treatment-naive, metastatic WT NSCLC with high PD-L1 expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Self-citationAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617
Nivolumab plus ipilimumab in advanced non-small-cell lung cancer
Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910231 · Cited by 2,823
Reck, M., Rodríguez–Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00149 · Cited by 1,670
West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30167-6 · Cited by 1,662
Sezer, A., Kilickap, S., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Turk, H. M., Cicin, I., Bentsion, D., Gladkov, O., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00228-2 · Cited by 789
Robins, J. M., & Tsiatis, A. A. (1991) · Communications in Statistics - Theory and Methods · doi:10.1080/03610929108830654 · Cited by 423
Cited by
Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.013 · Cited by 620
Brahmer, J. R., Lee, J.-S., Ciuleanu, T.-E., Bernabe Caro, R., Nishio, M., Urban, L., Audigier-Valette, C., Lupinacci, L., Sangha, R., Pluzanski, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01503 · Cited by 406
Sholl, L. M., Awad, M., Basu Roy, U., Beasley, M. B., Cartun, R. W., Hwang, D. M., Kalemkerian, G., Lopez-Rios, F., Mino-Kenudson, M., Paintal, A., et al. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2023-0536-cp · Cited by 38
Zhou, C., Wang, Z., Sun, M., Cao, L., Ma, Z., Wu, R., Yu, Y., Yao, W., Sun, S., Chen, J., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00198-6 · Cited by 23
Ahn, J., & Nagasaka, M. (2023) · Cancer Management and Research · doi:10.2147/cmar.s325856 · Cited by 12
Metadata
- Authors
- Jassem, J., de Marinis, F., Giaccone, G., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Oprean, C., Kim, Y.-C., Andric, Z., Mocci, S., Enquist, I., Komatsubara, K., McCleland, M., Kuriki, H., Villalobos, M., Phan, S., Spigel, D. R., & Herbst, R. S.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 16
- Issue
- 11
- Pages
- 1872-1882
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W3182948012
- Cited by
- 211
- References
- 9
- FWCI
- 10.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC. https://app.cochat.ai/papers/10.1016/j.jtho.2021.06.019
- The paper
- Jassem, J., de Marinis, F., Giaccone, G., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Oprean, C., Kim, Y.-C., Andric, Z., Mocci, S., Enquist, I., Komatsubara, K., McCleland, M., Kuriki, H., Villalobos, M., Phan, S., Spigel, D. R., & Herbst, R. S. (2021). Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2021.06.019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.